ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2674 • 2013 ACR/ARHP Annual Meeting

    Vitamin D Deficiency Is Common and Associated With Increased C-Reactive Protein In Children With Lupus: An Atherosclerosis Prevention In Pediatric Lupus Erythematosus Substudy

    Angela B. Robinson1, Vin Tangpricha2, Eric Yow3, Reut Gurion4, Grace McComsey4 and Laura E. Schanberg5, 1Pediatric Infectious Disease, Rheumatology and Geographic Medicine, Rainbow Babies and Children's Hospital / Case Medical Center, Cleveland, OH, 2Medicine, Emory University School of Medicine, Atlanta, GA, 3Biostatistics, Duke Clinical Research Institute, Durham, NC, 4Pediatric Infectious Diseases, Rheumatology, and Geographic Medicine, Rainbow Babies and Children's Hospital / Case Medical Center, Cleveland, OH, 5Pediatrics, Duke University Medical Center, Durham, NC

    Background/Purpose: Epidemiologic associations suggest vitamin D may play a role in inflammation and progression of atherosclerosis. Using frozen serum, carotid intima medial thickness (CIMT) measurements,…
  • Abstract Number: 2635 • 2013 ACR/ARHP Annual Meeting

    IgA Vasculitis In Adults – a Rare and Benign Disease?

    Alojzija Hocevar1, Jaka Ostrovrsnik1, Vesna Jurcic2 and Matija Tomsic3,4, 1Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, 2Institute of Pathology, University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia, 3Department of Rheumatology, University Medical Centre Ljubjana, Ljubljana, Slovenia, 4Faculty of Medicine, Unversity Ljubljana, Ljubljana, Slovenia

    Background/Purpose: IgA vasculitis (IgAV) is the most common vasculitis in children, with a defined epidemiology (14 cases/ 105children), clinical picture and generally favourable prognosis. In…
  • Abstract Number: 2636 • 2013 ACR/ARHP Annual Meeting

    IgA Vasculitis – The Second Most Common Systemic Vasculitis In Adults In Slovenia

    Alojzija Hocevar1, ŽIga Rotar1, Jaka Ostrovrsnik1, Vesna Jurcic2, Jelka Lindic3 and Matija Tomsic4,5, 1Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, 2Institute of Pathology, University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia, 3Department of Nephrology, University Medical Centre Ljubljana, Ljubljana, Slovenia, 4Department of Rheumatology, University Medical Centre Ljubjana, Ljubljana, Slovenia, 5Faculty of Medicine, Unversity Ljubljana, Ljubljana, Slovenia

    Background/Purpose: IgA vasculitis (IgAV) is assumed to be rare in adults. Reported annual incidence rates vary between 0.8 and 1.8 cases per 100,000 adults.1 Our…
  • Abstract Number: 2637 • 2013 ACR/ARHP Annual Meeting

    Validation Study Of The International Classification Criteria For The Cryoglobulinemic Vasculitis

    Luca Quartuccio1, Miriam Isola2, Laura Corazza3, Soledad Retamozo4, Manal Abdel-Moneim El-Menyawi5, Elisa Gremese6, Marco Sebastiani7, Nicolo Pipitone8, Teresa Urraro9, Vincenza Conteduca10, Christos Koutsianas11, Benjamin Terrier12, Mostafa Naguib Zoheir13, Alessandra Ghinoi14, Davide Filippini15, Francesco Saccardo16, Mohamed Nabil Salem17, Salvatore Scarpato18, Paolo Fraticelli19, Antonio Tavoni20, Eleonora Catarsi21, Cesare Mazzaro22, Pietro Pioltelli23, Mervat Matar5, Patrizia Scaini24, Matija Tomsic25, Norihiro Nishimoto26,27, Dimitrios Vassilopoulos28, Michael Voulgarelis29, Gaafar M. Ragab30, Carlo Salvarani31, Armando Gabrielli32, Patrice Cacoub33, Loic Guillevin34, Domenico Sansonno35, Anna Linda Zignego36, Gianfranco Ferraccioli6, Athanasios G. Tzioufas37, Manuel Ramos-Casals38, Clodoveo Ferri39, Maurizio Pietrogrande40, Giuseppe Monti16, Massimo Galli41, Stefano Bombardieri42 and Salvatore De Vita43, 1Rheumatology Clinic, DSMB, University of Udine, Udine, Italy, 2Institute of Statistics, DSMB, University of Udine, Udine, Italy, 3Rheumatology Clinic, University of Udine, Udine, Italy, 4Laboratorio de Enfermedades Autoinmunes Josep Font, IDIBAPS, Hospital Clínic, Barcelona, Spain, 5Faculty of Medicine, Cairo, Egypt, 6Division of Rheumatology, Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy, 7Internal Medicine, University of Modena and Reggio Emilia, Modena, Italy, 8Rheumatology Service, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, 9Center for Systemic Manifestations of Hepatitis Viruses (MASVE), Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, 10Department of Internal Medicine and Clinical Oncology, University of Bari, Bari, Italy, 11Department of Pathophysiology, Medical School of Athens, Athens, Greece, 12Internal Medicine, Cochin University Hospital, Paris, France, 13Faculty of Medicine, Cairo University, Cairo, Egypt, 14Rheumatology, Arcispedale S Maria Nuova, Reggio Emilia, Italy, 15Rheumatology Unit, Ospedale Niguarda,, Milan, Italy, 16Internal Medicine Unit, Saronno Hospital, Azienda Ospedaliera di Busto Arsizio, Saronno (VA), Italy, 17Faculty of Medicine, Beni Swafe University, Beni Swafe, Egypt, 18Rheumatology Unit, M. Scarlato Hospital, Scafati, Salerno, Italy, 19Istituto di Clinica Medica, Università Politecnica delle Marche, Ancona, Italy, 20University of Pisa, Immunoallergology Unit, Pisa, Italy, 21Department of Internal Medicine, Section of Immunoallergology, University of Pisa, Pisa, Italy, 22Department of Internal Medicine, Pordenone General Hospital, Pordenone, Italy, 23Hematology, S.Gerardo Hospital, Monza, Italy, 24Nephrology, Spedali Civili di Brescia, Brescia, Italy, 25Department of Rheumatology, University Medical Centre Ljubjana, Ljubljana, Slovenia, 26Laboratory of Immune Regulation, Wakayama Medical University, Ibaraki, Japan, 27Osaka Rheumatology Clinic, Osaka, Japan, 282nd Department of Medicine, Athens University School of Medicine, Athens, Greece, 29School of Medicine, University, Department of Pathophysiology, Athens, Greece, 30Int Medicine Hosp/Rheum&Immun, Faculty of Medicine, Cairo University, Giza, Egypt, 31Rheumatology, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, 32Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, Italy, 33Médecine Interne 2, Hopital Pitié-Salpétrière, Paris, France, 34Internal Medicine, Division of Internal Medicine, Hôpital Cochin, University Paris Descartes, Paris, France, 35Section of Internal Medicine and Clinical Oncology, Department of Biomedical Sciences and Human Oncology, University of Bari, Medical School, Bari, Italy, 36University of Florence, Center for Systemic Manifestations of Hepatitis Viruses (MASVE), Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, 37Pathophysiology, School of Medicine, National University of Athens, Athens, Greece, 38Laboratorio de Enfermedades Autoinmunes Josep Font, Hospital Clínic, Barcelona, Spain, 39Department of Internal Medicine, University of Modena and Reggio Emilia, Modena, Italy, 40Internal Medicine Unit, Policlinico San Marco, Bergamo, Italy, 41Istituto di Malattie Infettive e Tropicali, Università di Milano c/o Ospedale L. Sacco, Milano, Italy, 42Department of Clinical and Experimental Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, 43Rheumatology, DSMB, University Hospital Santa Maria della Misericordia, Udine, Italy

    Background/Purpose: preliminary Classification Criteria for cryoglobulinemic vasculitis (CV) have been developed in 2011 by an European cooperative study, with an adequate methodology in a large…
  • Abstract Number: 2638 • 2013 ACR/ARHP Annual Meeting

    Cryoglobulinemia Vasculitis With Or Without Associated Cryofibrinogenemia: A Different Phenotype?

    Martin Michaud1, Guillaume Moulis2, Jacques Pourrat1, Benedicte Puissant1, Antoine Blancher1 and Laurent Sailler3, 1Toulouse University Hospital, University of Toulouse, Toulouse, France, 2Toulouse University Hospital, Clinical Pharmacology Department, University of Toulouse, UMR INSERM-UPS 1027, Toulouse, France, 3Department of Internal Medicine, Toulouse University Hospital, Toulouse, France

    Background/Purpose: Cryoglobulin (CryoGl) and cryofibrinogen (CryoFg) are cryoproteins, both responsible for well-described systemic vasculitis. Nevertheless, cryoglobulinemia may be associated with cryofibrinogenemia. Such mixed cryoprotein vasculitis…
  • Abstract Number: 2639 • 2013 ACR/ARHP Annual Meeting

    Long-Term Outcome of Monoclonal (type 1) Cryoglobulinemia

    Antoine Néel1, François Perrin1, Olivier Decaux2, Thomas Dejoie3, Maxime Halliez3, Béatrice Mahé4, Thierry Lamy5, Fadi Fakhouri6, Patrick Jego2, Christian Agard1, Cécile Vigneau7, Lucienne Guenet8, Bernard Grosbois9, Philippe Moreau4 and Mohamed Hamidou1, 1Internal Medicine Department, Nantes University Hospital, Nantes, France, 2Department of Internal Medicine, Rennes University Hospital, Rennes, France, 3Biochemistry Laboratory, Nantes University Hospital, Nantes, France, 4Hematology, Nantes University Hospital, Nantes, France, 5Hematology, Rennes University Hospital, Rennes, France, 6Nephrology, Nantes University Hospital, Nantes, France, 7Nephrology, Rennes University Hospital, Rennes, France, 8Biochemistry Laboratory, Rennes University Hospital, Rennes, France, 9Internal Medicine Department, Rennes University Hospital, Rennes, France

    Background/Purpose: To investigate long-term outcome of symptomatic type 1 cryoglobulinemia and its determinants. Methods: Retrospective analysis of a prospective cohort from 2 French university hospitals.…
  • Abstract Number: 2640 • 2013 ACR/ARHP Annual Meeting

    VERY LONG-TERM Effects Of The “4 PLUS2 Infusion PROTOCOL” Of Rituximabalone In Patients With HCV-Associatedmixed Cryoglobulinemia With Diffusemembranoproliferative Glomerulonephritis,Severe Polyneuropathy and Necrotic Ulcersof Skin

    Dario Roccatello1, Savino Sciascia1, Simone Baldovino2 and Daniela Rossi1, 1Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, Centro di Immunopatologia e Documentazione su Malattie rare, Torino, Italy, 2Centro di Ricerche di Immunologia Clinica ed Immunopatologia e Documentazione su Malattie Rare (CMID), Università di Torino, Torino, Italy

    Background/Purpose: Mixed cryoglobulinemia syndrome (MCs) is a systemic vasculitischaracterized by multiple organ involvement due to the vascular deposition ofIgMk/IgG cryoglobulins. B cells expansion usually triggered…
  • Abstract Number: 2641 • 2013 ACR/ARHP Annual Meeting

    Earlier Admission To Specialized Care, Intensified Treatment and Improved Outcome In Patients With Autoimmune Connective Tissue Disorders and Vasculitides In Germany 2011 Compared To 1995

    Dörte Huscher1, Katinka Albrecht2, Katja Thiele2, Sascha Bischoff2, Jutta G. Richter3, Ina Kötter4, Wolfgang Ochs5 and Angela Zink1, 1German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany, 2German Rheumatism Research Centre, Berlin, Germany, 3Department of Rheumatology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, 4ZIRS, Centre for Interdisciplinary Rheumatology Stuttgart, Stuttgart, Germany, 5Rheumatologist in private practice, Bayreuth, Germany

    Background/Purpose: Compared to rheumatoid arthritis and other arthritis-associated rheumatic diseases, autoimmune connective tissue disorders and vasculitides are still in the early stages of biological therapies.…
  • Abstract Number: 2642 • 2013 ACR/ARHP Annual Meeting

    A Novel Genetic Basis For Systemic Vasculitis: Polyarteritis Nodosa Caused By Recessive Mutations In An Immune-Related Gene

    Reeval Segel1,2, Pnina Elkan-Navon3, Sarah B. Pierce4, Tom Walsh4, Judith Barash5, Shay Padeh6, Avraham Zlotogorski7, Yackov Berkun8, Isabel Voth9, Philip Hashkes10, Liora Harel11, Eduard Ling12, Fatos Yalcinkaya13, Ozgur Kasapcopur14, Paul F. Renbaum15, Ariella Weinberg-Shukron15, Barbara Schormair16, Mordechai Shohat17, Alan A. Rubinow18, Elon Pras19, Juliane Winkelmann20, Mustafa Tekin21, Yair Anikster22, Mary-Claire King4 and Ephrat Levy-Lahad15, 1Medical Genetics and Pediatrics, Shaare Zedek Medical Center, Jerusalem, Israel, 2Hebrew University Medical School, Jerusalem, Israel, 3Pediatrics, Shaare Zedek Medical Center, Jerusalem, Israel, 4Medical Genetics, University of Washington, Seattle, WA, 5Pediatric Day Care, Kaplan Medical Center, Rehovot, Israel, 6Pediatrics, Sheba Medical Center, Ramat Gan, Israel, 7Department of Dermatology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel, 8Pediatrics, Hadassah Medical Center, Mount Scopus, Jerusalem, Israel, 9Department of Neurology, Technische Universitat Munchen Klinikum rechts der Isar, Munich, Germany, 10Pediatric Rheumatology, Shaare Zedek Medical Center, Jerusalem, Israel, 11Pediatric Rheumatology unit, Schneider Children's Medical Center, Tel Aviv University, Petach Tikvah, Israel, 12Rheumatology Unit, Soroka University Medical Center and Ben-Gurion University, Beer-Sheva, Beer Sheva, Israel, 13Pediatric Nephrology and Rheumatology, Ankara University, Ankara, Turkey, 14Ankara University, Ankara, Turkey, 15Medical Genetics, Shaare Zedek Medical Center, Jerusalem, Israel, 16Helmholtz Zentrum Munchen, Munich, Germany, 17Rafael Recanati medical genetics Institute, Rabin Medical Center, Beilinson Hospital, Petach Tikvah, Israel, 18Hadassah Medical Center, Jerusalem, Israel, 19Institute of Human Genetics, Sheba Medical Center, Ramat Gan, Israel, 20Genetics, Stanford University, San Francisco, CA, 21Dr. John T. Macdonald Foundation Department of Human Genetics and John P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, FL, 22Metabolic Disease Unit, Sheba Medical Center, Ramat Gan, Israel

    Background/Purpose: Polyarteritis nodosa (PAN) is a systemic necrotizing vasculitis. Disease pathogenesis and possible genetic factors are poorly understood.  We identified familial, mostly pediatric PAN, in…
  • Abstract Number: 2643 • 2013 ACR/ARHP Annual Meeting

    Midkine Is a Novel Prognostic Factor In Patients With Vasculitis Syndrome

    Yoshie Kusunoki1, Yutaka Okano1, Natsuko Kusunoki2, Natsuki Fujio2, Mai Kawazoe2, Emiko Shindo2, Kotaro Shikano2, Makoto Kaburaki2, Sei Muraoka2, Kanako Kitahara2, Kaichi Kaneko2, Nahoko Tanaka2, Tatsuhiro Yamamoto2, Kenji Takagi2, Tomoko Hasunuma2, Hirahito Endo2 and Shinichi Kawai2, 1Center for Arthritis and Rheumatic Diseases, Kawasaki Municipal Kawasaki Hospital, Kanagawa, Japan, 2Division of Rheumatology, Department of Internal Medicine, School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan

    Background/Purpose: Midkine (MK) is a heparin-binding growth factor, promotes growth, survival, and migration of various cells. Recently several reports show that MK may also play…
  • Abstract Number: 2644 • 2013 ACR/ARHP Annual Meeting

    Phase IB/Iia Study On Intravenous Administration Of Expanded Allogeneic Adipose-Derived Mesenchymal Stem Cells In Refractory Rheumatoid Arthritis Patients

    JM Alvaro-Gracia1, Juan A. Jover2, Rosario Garcia-Vicuña3, Luis Carreño4, Alberto Alonso5, Sara Marsal6, Francisco J. Blanco7, Víctor M. Martínez-Taboada8, Peter C. Taylor9, Federico Díaz-González10 and Lydia Dorrego11, 1Unidad de Terapias Biológicas. Servicio de Reumatología, Hospital Universitario de La Princesa, Madrid, Spain, 2Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, 3Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, 4Rheumatology, Gregorio Marañón Hospital, Madrid, Spain, 5Hospital de Cruces, Bilbao, Spain, 6Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, 7INIBIC-Hospital Universitario A Coruña. Rheumatology Division. Genomic Group, A Coruña, Spain, 8Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV., Santander, Spain, 9NDORMS, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, 10Hospital Universitario de Canarias, La Laguna. Tenerife, Spain, 11TiGenix, Tres Cantos, Spain

    Background/Purpose: Expanded adipose-derived stem cells (eASCs) are shown to have immune-modulatory effects both in vitro and in animal models of arthritis. eASCs are currently under…
  • Abstract Number: 2645 • 2013 ACR/ARHP Annual Meeting

    Pathological Roles Of The Anti-Oxidative Enzyme Peroxiredoxin 2 In Patients With Kawasaki Disease

    Rie Karasawa1, Toshiko Sato1, Mayumi Tamaki1, Mikiya Fujieda2, Kazuhide Ohta3 and Kazuo Yudoh1, 1Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan, 2Department of Pediatrics, Kochi Medical School, Nankoku, Japan, 3Department of Pediatrics, Kanazawa Medical Center, Kanazawa, Japan

    Background/Purpose: Anti-endothelial cell antibodies (AECA) are autoantibodies that are detected frequently in vasculitis caused by, for example, Kawasaki disease (KD). However, AECA target molecules have…
  • Abstract Number: 2646 • 2013 ACR/ARHP Annual Meeting

    Cost-Effectiveness Analysis Of Triple Therapy Versus Etanercept Plus Methotrexate In Early Aggressive Rheumatoid Arthritis: Analysis Based On The TEAR Trial

    Hawre Jalal1, Jeffrey R. Curtis2, Stacey Cofield3, Larry W. Moreland4, James R. O'Dell5 and Kaleb Michaud6, 1Health Polisy and Management, University of Minnesota, Minneapolis, MN, 2Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 3University of Alabama at Birmingham, Birmingham, AL, 4University of Pittsburgh, Pittsburgh, PA, 5Veteran Affairs Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, 6Rheumatology, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: The long-term cost-effectiveness of triple therapy (methotrexate [MTX], sulfasalazine [SSZ], hydroxychloroquine [HCQ]) disease modifying anti-rheumatic drugs (DMARDs) compared to a combination of MTX and…
  • Abstract Number: 2647 • 2013 ACR/ARHP Annual Meeting

    Recombinant Monoclonal Antibodies Derived From Single CD19+ Synovial B Cells Of RA Patients With Tertiary Lymphoid Structures Display a Strong Immunoreactivity Towards Citrullinated Histones

    Elisa Corsiero1, Michele Bombardieri2, Emanuela Carlotti1, Hedda Wardemann3, William H. Robinson4 and Costantino Pitzalis1, 1Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, QMUL, London, United Kingdom, 2Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom, 3Max Planck Research Group Molecular Immunology, Max Planck Institute for Infection Biology, Berlin, Germany, 4Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA

    Background/Purpose: Rheumatoid arthritis (RA) is characterised by breach of self-tolerance towards citrullinated proteins. Around 40% of patients display synovial tertiary lymphoid structures (TLS) with functional…
  • Abstract Number: 2648 • 2013 ACR/ARHP Annual Meeting

    Characterization Of Histidyl-tRNA Synthetase Specific Th Cell Response In Blood and Broncheoalveolar Lavage (BAL) Of Myositis Patients

    Inka Albrecht1, Eddie James2, Maryam Fathi3, Maryam Dastmalchi4, Jessica Herrath1, Vivianne Malmström5 and Ingrid E. Lundberg6, 1Department of Medicine, Solna, Unit of Rheumatology, Karolinska University Hospital, Department of Medicine, Solna, Unit of Rheumatology, Stockholm, Sweden, 2Benaroya Research Institute, Seattle, WA, 3Karolinska Institutet, Department of Medicine , Respiratory Medicine Unit, Stockholm, Sweden, 4Department of Medicine, Karolinska University Hospital, Department of Medicine, Solna, Unit of Rheumatology, Stockholm, Sweden, 5Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 6Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose:  Idiopathic inflammatory myopathy is a rare chronic inflammatory disease that is associated with the presence of autoantibodies pointing to a contribution of adaptive immune…
  • « Previous Page
  • 1
  • …
  • 2073
  • 2074
  • 2075
  • 2076
  • 2077
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology